Home

American Association of Diabetes Educators

Find an Education Program MY AADE NETWORK Online Store AADE18 About AADE JOIN AADE
JOIN AADE
 

AstraZeneca Educational Webinar Series

Presented by AADE in association with AstraZeneca-US Medical Affairs, CVMD Division

This educational webinar series is designed to provide the most up-to-date, cutting edge information in diabetes. Each webinar will be presented live and recorded. Archived presentations will be posted on this page for up to 40 days after the live broadcast, so don't miss out!

This webinar series is educational in nature and contains no promotional or product information. CE credit is not available for this activity.





Webinar Schedule:

October 17: Cardiovascular Disease and Type 2 Diabetes: Defining The Therapeutic Crossroads 




Achieving and Maintaining Glycemic Control Early in T2D with Combination Therapy


Presented by Jason Moran, PhD, and Curtis Triplitt, PharmD, CDE, this webinar will review the pathophysiology that contributes to the onset and progression of T2D as well as challenges in achieving glucose targets and the consequences of 'glycemic legacy'. Faculty will discuss the role of current therapeutic options in addressing underlying defects and the clinical value of achieving and maintaining intensive glucose control early in T2D.

Upon completion of this activity, participants will be able to:

  1. Understand the pathophysiology of T2D onset and progression and the role of current therapeutic options
  2. Appreciate the challenges of achieving and maintaining glucose targets
  3. Understand "glycemic legacy" and the scientific rationale for instituting intensive T2D therapy early in disease progression



Coming Soon: Cardiovascular Disease and Type 2 Diabetes: Defining The Therapeutic Crossroads

Click here to register for this live webinar on Wednesday, October 17, 2018 at 1:00 pm EST.

Presented by Narinder Bhalla, MD, FACC, FSCAI, and Curtis Triplitt, PharmD, CDE, this webinar will focus on the intersection of cardiovascular disease and diabetes. It will start with the types of CVD encountered in patients with T2D, and their overall frequency, associated features and prognosis. We will define primary and secondary prevention and some of the nuanced differences in the definitions amongst cardiologists and diabetologists/endocrinologists. We will go through the tried and true therapies in managing CVD in patients with T2D, and some of the controversy surrounding the role of aspirin in primary prevention (some of the recent trial will be discussed). The EASD updated statement in managing patients with T2DM will be discussed, and will be used as an example of the changing paradigm of using the presence of CVD as a pivot point in the treatment. We will then end with the future trials, and their designs and the questions they will seek to answer.

Upon completion of this activity, participants will be able to:

  1. Understand the epidemiology of the various cardiovascular comorbidities that coexist in the patient with T2D
  2. Be able to discuss primary and secondary prevention and understand the definitions
  3. Understand the new paradigm in treating patients with diabetes, with the type of CVD being a pivot point in treatment choices